Malignant neoplasm of splenic flexure
ICD-10 C18.5 is a billable code used to indicate a diagnosis of malignant neoplasm of splenic flexure.
C18.5 refers to a malignant neoplasm located at the splenic flexure of the colon, which is the bend in the colon near the spleen. This type of cancer is part of colorectal cancer, which is characterized by the uncontrolled growth of abnormal cells in the colon or rectum. The splenic flexure is a critical area where the transverse colon transitions into the descending colon. Symptoms may include abdominal pain, changes in bowel habits, weight loss, and rectal bleeding. Diagnosis typically involves imaging studies, colonoscopy, and biopsy. Staging of colorectal cancer is crucial for determining the extent of disease and guiding treatment options, which may include surgery, chemotherapy, and radiation therapy. The presence of microsatellite instability (MSI) can indicate a specific subtype of colorectal cancer that may respond differently to treatment. Early detection through screening methods such as colonoscopy is vital for improving outcomes, as colorectal cancer is often asymptomatic in its early stages.
Detailed pathology reports, imaging studies, and treatment plans.
Diagnosis and treatment planning for colorectal cancer, follow-up care.
Ensure accurate staging and documentation of treatment response.
Colonoscopy reports, biopsy results, and patient history.
Screening for colorectal cancer, management of symptoms.
Document findings from colonoscopy and any polyps or lesions.
Used for initial diagnosis and surveillance of colorectal cancer.
Colonoscopy report detailing findings and any biopsies taken.
Gastroenterologists must document the extent of the procedure and findings.
Performed for resection of malignant neoplasm at the splenic flexure.
Operative report detailing the procedure and pathology results.
Surgeons must ensure accurate coding based on the extent of resection.
Microsatellite instability (MSI) is a condition of genetic hypermutability that can occur in colorectal cancer. It is significant because tumors with MSI may respond differently to certain treatments, such as immunotherapy, and can indicate a hereditary cancer syndrome.
